Fluoxetine augmentation in citalopram non-responders: Pharmacokinetic and clinical consequences

International Journal of Neuropsychopharmacology

Volumn 3, Issue 1, 2000, Pages 55-60

  Bondolfi, Guido ^a,b   Lissner, Catherine ^a,b   Kosel, Markus ^a   Eap, Chin B ^a   Baumann, Pierre ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Citalopram; Depression; Fluoxetine; Pharmacokinetic interaction

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DEBRISOQUINE 4 HYDROXYLASE; DEXTROMETHORPHAN; FLUOXETINE; MEPHENYTOIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; ENANTIOMER; ENZYME INHIBITION; FEMALE; HUMAN; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; STEREOCHEMISTRY;

EID: 0034086125     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145799001686     Document Type: Article

References (32)

1. Baker GB, Fang J, Sinha S, Coutts RT (1998). Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants. Neuroscience and Biobehavioral Reviews 22, 325-333.
2. Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier-Perey M, Koeb L, Monney C, Woggon B (1992). Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Therapeutic Drug Monitoring 14, 1-8.
3. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, Kasas A, Amey M, Jonzier-Perey M (1996). A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. Journal of Clinical Psychopharmacology 16, 307-314.
4. Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P (1996). Nonresponse to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology 128, 421-425.
5. Brosen K (1995). Drug interactions and the cytochrome P450 system: the role of cytochrome P450 1A2. Clinical Pharmacokinetics 29 (Suppl. 1), 20-25.
6. Brown WA, Harrison W (1995). Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? Journal of Clinical Psychiatry 56, 30-34.
7. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992). The effect of selective serotonin re-uptake inhibitors on cytochrome P450 2D6 (CYP2D6) activity in human liver microsomes. British Journal of Clinical Pharmacology 34, 262-265.
8. de Jonghe F, Swinkels J (1997). Selective serotonin reuptake inhibitors -relevance of differences in their pharmacological and clinical profiles. CNS Drugs 7, 452-467.
9. Eap CB, Gaillard N, Powell K, Baumann P (1996). Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. Journal of Chromatography B: Biomedical Applications 682, 265-272.
10. Fjordside L, Jeppesen U, Eap CB, Powell K, Baumann P, Brosen K (1999). The stereoselective metabolism of fluoxetine in poor and extensive metabolisers of sparteine. Pharmacogenetics 9, 55-60.
11. Foglia JP, Pollock BG, Kirshner MA, Rosen J, Sweet R, Mulsant B (1997). Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacological Bulletin 33(1), 109-112.
12. Greenblatt DJ, Von Moltke LL, Harmatz JS, Shader RI (1998). Drug interactions with newer antidepressants: role of human cytochromes P450. Journal of Clinical Psychiatry 59 (Suppl. 15), 19-27.
13. Hyttel J, Amt J, Sanchez C (1995). The pharmacology of citalopram. Reviews in Contemporary Pharmacotherapy 6, 271-285.
14. Hyttel J, Bogeso KP, Perregaard J, Sanchez C (1992). The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. Journal of Neural Transmission (General Section) 88, 157-160.
15. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T, Kuroiwa Y (1997). Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 280, 927-933.
16. Kobayashi K, Yamamoto T, Chiba K, Tani M, Ishizaki T, Kuroiwa Y (1995). The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. British Journal of Clinical Pharmacology 40, 481-485.
17. Kosel M, Eap CB, Amey M, Baumann P (1998). Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography. Journal of Chromatography B: Biomedical Applications 719, 234-238.
18. Mittmann N, Mitter S, Borden EK, Herrmenn N, Naranjo C, Shear NH (1997). Montgomery-Asberg severity gradations. American Journal of Psychiatry 154, 1320-1321.
19. Montgomery SA, Pedersen V, Tanghoj P, Rasmussen C, Rioux P (1994). The optimal dosing regimen for citalopram-a meta-analysis of nine placebo-controlled studies. International Clinical Psychopharmacology 9 (Suppl. 1), 35-40.
20. Rochat B, Amey M, Baumann P (1995). Analysis of the enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Therapeutic Drug Monitoring 17, 273-279.
21. Rochat B, Amey M, Gillet M, Meyer UA, Baumann P (1997). Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 7, 1-10.
22. Rochat B, Kosel M, Boss G, Testa B, Gillet M, Baumann P (1998). Stereoselective biotransformation of the selective serotonin reuptake inhibitor, citalopram, and its demethylated metabolites by monoamine oxidases in human liver. Biochemical Pharmacology 56, 15-23.
23. Sacchetti E, Conte G, Guarneri L (1994). Are SSRI antidepressants a clinically homogeneous class of compounds? [letter]. Lancet 344, 126-127.
24. Sanchez C, Meier E (1997). Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression - are they all alike? Psychopharmacology 129, 197-205.
25. Schmider J, Greenblatt DJ, Von Moltke LL, Karsov D, Shader RI (1997). Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. British Journal of Clinical Pharmacology 44, 495-498.
26. Sidhu J, Priskom M, Poulsen M, Segonzac A, Grollier G, Larsen F (1997). Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9, 686-692.
27. Sindrup SH, Brosen K, Hansen MGJ, Aaes-Jorgensen T, Fredricson Overo K, Gram LF (1993). Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Therapeutic Drug Monitoring 15, 11-17.
28. Spina E, Avenoso SA, Facciola G, Fabrazzo M, Monteleone P, Maj M, Perucca E, Caputi AE (1998). Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. International Clinical Psychopharmacology 13, 141-145.
29. Stevens JC, Wrighton SA (1993). Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. Journal of Pharmacology and Experimental Therapeutics 266, 964-971.
30. Thummel KE, Wilkinson GR (1998). In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology 38, 389-430.
31. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, François T, Sechter D, Bizouard P (1995). Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine, and neuroleptics in phenotyped patients. Pharmacological Research 31, 347-353.
32. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Wright CE, Harmatz JS, Shader RI (1997). Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology 132, 402-407.